GSK1016790A

Add links
Source: Wikipedia, the free encyclopedia.
GSK1016790A
Identifiers
  • N-[(1S)-1-[[4-[(2S)-2-[[(2,4-Dichlorophenyl)sulfonyl]amino]-3-hydroxy-1-oxopropyl]-1-piperazinyl]carbonyl]-3-methylbutyl]benzo[b]thiophene-2-carboxamide
JSmol)
  • CC(C)C[C@H](NC(C1=CC2=CC=CC=C2S1)=O)C(N3CCN(CC3)C([C@H](CO)NS(=O)(C4=C(Cl)C=C(Cl)C=C4)=O)=O)=O
  • InChI=1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1
  • Key:IVYQPSHHYIAUFO-VXKWHMMOSA-N

GSK1016790A (aka GSK101) is a drug developed by

bladder.[1][2][3][4][5]

References

  1. S2CID 517735
    .
  2. PMID 21671873
    .
  3. S2CID 212406213
    .
  4. S2CID 219959586
    .
  5. S2CID 220731478
    .
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=GSK1016790A&oldid=1182789881"